Anaveon announces presentation of new data on development compounds ANV700 and ANV600 at the Society for Immunotherapy of Cancer 2024 Annual Meeting
30. Oktober 2024 03:00 ET
|
Anaveon
Anaveon announces presentation of new data on development compounds ANV700 and ANV600 at the Society for Immunotherapy of Cancer 2024 Annual Meeting
Anaveon appoints Dieter Weinand as Chair of its Board of Directors
30. Juli 2024 02:00 ET
|
Anaveon
BASEL, Switzerland, July 30, 2024 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced the appointment of Dieter Weinand, former Chair and CEO of Bayer...
Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
29. Mai 2024 02:00 ET
|
Anaveon
Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
Anaveon announces presentation of a novel development compound at the 2023 American Association for Cancer Research Annual Meeting
23. März 2023 03:00 ET
|
Anaveon
BASEL, Switzerland, March 23, 2023 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced that it will present a poster on ANV600 at the American Association for...
Anaveon announces first patient dosed with ANV419 in a Phase I/II Study of ANV419 in patients with multiple myeloma
16. März 2023 03:00 ET
|
Anaveon
BASEL, Switzerland, March 16, 2023 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced the first patient dosed with ANV419 in the OMNIA-2 (ANV419-102) study - a...
Anaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in combination with check point inhibitors in patients with advanced melanoma
02. Februar 2023 02:00 ET
|
Anaveon
BASEL, Switzerland, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Anaveon, a clinical stage, immuno-oncology company, today announced the first patient has been dosed in the OMNIA-1 study – a Phase I/II study...
Anaveon presents updated data from the Phase I/II study of ANV419 during the ESMO Congress 2022
10. September 2022 03:00 ET
|
Anaveon
- ANV419 is well-tolerated at high doses and demonstrates notable safety with strong pharmacodynamic effects and excellent IL-2Rbg selectivity – - A Phase II program of ANV419 has been initiated in...
Anaveon presents compelling data from the Phase I/II study of ANV419 during the AACR Annual Meeting 2022
08. April 2022 13:00 ET
|
Anaveon
- ANV419 is very well-tolerated and demonstrates exceptional safety with strong pharmacodynamic effects and excellent IL-2Rβγ selectivity - - A Phase II program of ANV419 has been initiated in...
Anaveon to raise CHF 110 million in oversubscribed Series B financing
16. Dezember 2021 02:00 ET
|
Anaveon
- Leading international syndicate led by Forbion and corner-stoned by founding investor Syncona- Confirms depth of support for Anaveon’s approach to developing engineered cytokines in multiple...